Further analysis showed that the expression of GKN2 in LUAD with P53 mutation group was lower than that of the P53 non‐mutation group (Figure 1Fp < 0.001), and the prognosis of NSCLC did not differ significantly from the high or low level of GKN2 mRNA expression (p = 0.63) (Figure 1G). The gene discussed is TP53; the disease is non-small cell lung carcinoma.